Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Accumulated Expenses (2016 - 2022)

Usana Health Sciences (USNA) has disclosed Accumulated Expenses for 10 consecutive years, with $32.4 million as the latest value for Q1 2022.

  • Quarterly Accumulated Expenses rose 0.56% to $32.4 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $32.4 million through Jan 2022, up 0.56% year-over-year, with the annual reading at $32.4 million for FY2022, 0.56% up from the prior year.
  • Accumulated Expenses for Q1 2022 was $32.4 million at Usana Health Sciences, up from $32.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $33.7 million in Q4 2018, with the low at $26.2 million in Q4 2019.
  • Average Accumulated Expenses over 4 years is $31.1 million, with a median of $32.3 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses soared 47.13% in 2018, then fell 22.41% in 2019.
  • Over 4 years, Accumulated Expenses stood at $33.7 million in 2018, then dropped by 22.41% to $26.2 million in 2019, then increased by 23.07% to $32.2 million in 2021, then rose by 0.56% to $32.4 million in 2022.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $32.4 million, $32.2 million, and $26.2 million for Q1 2022, Q1 2021, and Q4 2019 respectively.